Latest news with #elastin
Vogue Arabia
15 hours ago
- Health
- Vogue Arabia
High Facial Cortisol: 5 Microhabits to Reduce it
High facial cortisol: what is it and how does it manifest itself? 'Without cortisol we are dead', say many experts. This stress hormone on which the capricious algorithm of Google and social networks constantly suggests topics to us, is necessary to live and function. Let's say it is a mechanism of survival and defense. The problem is when it is triggered in an excessive and constant way, the balance is broken and the consequences begin in the form of weight gain, insomnia, mood alteration, digestive problems... The list of consequences is as long as life itself, but if we stick to the field of skin, there are also a few because when you live in a state of alert you stop producing collagen and elastin, and that translates into a less firm and elastic skin (among other things). Precisely for this reason we are already talking about cutaneous cortisol or facial cortisol and it is an aspect that wellness expert Claudia Di Paolo has explored in depth. "The skin and scalp are living, biologically active and emotionally reactive organs. Cutaneous cortisol is the manifestation of stress on the skin. It is, in essence, an accelerator of visible aging and silent inflammation that we do not always perceive, but that conditions its vitality," he reflects. Symptoms of high facial cortisol As explained by the creator of the method Claudia Di Paolo Hair Wellness SpaWhen this natural defense mechanism goes out of control, certain obvious symptoms appear that are joined by another, less obvious to the eye: silent or chronic inflammation that affects the skin, degrading collagen and accelerating the signs of aging. But before that inflammation is seen, there are other signs that skin cortisol is high: Loss of hydration. Increased sensitivity. Dull tone. A slower ability to regenerate. Microhabits to Reduce Facial Cortisol It is important to remember that the skin does not produce cortisol on its own, but excess cortisol affects the skin and face and this skin response to stress is called facial cortisol. That said, we review with the help of Claudia Di Paolo small daily habits that can help us return the dermis to this state of balance or homeostasis that is so much talked about today: The rule of 10 The self-care may seem too coarse a word and somewhat unattainable, but it really doesn't take big gestures or large amounts of time to start taking care of it. That's why the expert talks about finding small moments for it, even if it's only 10 minutes. "They are key to that body, mind and skin balance," she says. Anti-inflammatory food This type of diet will not regulate cortisol, but it will modulate to some extent the silent inflammation that results from stress and unbalances the skin. That is why the expert insists on introducing foods rich in antioxidants (such as green tea); omega-3 (oily fish, nuts and seeds), and avoiding refined sugars to promote a more balanced skin. Breathe and meditate If meditating and trying to be present is difficult (it is not easy to achieve this state), the expert suggests exercises of conscious breathing to reduce stress and, therefore, cortisol. There are many alternatives although the most basic to start with is simply to breathe deeply inhaling air through the nose and releasing it through the mouth and pay attention to how the entry and exit of air in our body affects the movement of the ribs. Sleep As Tyra Banks used to say, sleep is the best cosmetic. And Di Paolo confirms it: "Sleeping well is the most natural and restorative treatment to balance hormone levels and restore the skin". That's why when you sleep better you are calmer, you eat better because you regulate the sensations of hunger and satiety... and that affects the skin. Neuroactive cosmetics There are products that only act at the dermal level (and they are wonderful) and others that accompany the formula with active ingredients capable of influencing the nervous system. This is neuroactive cosmetics, which goes to the source of biological stress through active ingredients and scents to create a sensory veil because "the skin is a neuroreceptive organ, with thousands of nerve endings that influence our emotional state," Di Paolo points out. Hence, cosmetics inspired by this skin neuroscience "activate the parasympathetic nervous system, promoting emotional relaxation and helping to reduce anxiety and stress. By modulating the skin's response to cortisol, these masks not only soothe the skin, but also generate a feeling of relief and relaxation," concludes the expert. Article originally published on Vogue Spain.
Yahoo
05-08-2025
- Business
- Yahoo
Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté
KB304 designed to deliver collagen and elastin to restore skin naturally Conference call to discuss results scheduled for Thursday, July 24, 2025 at 4:30pm ET PITTSBURGH, July 24, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ('Jeune'), a wholly owned subsidiary of Krystal Biotech, Inc. ('Krystal') (NASDAQ: KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally reverse the biology of aging skin, announced today positive safety and efficacy results, including significant improvements in key skin aesthetic attributes such as wrinkles and elasticity, in PEARL-2, a randomized, double-blind, placebo-controlled Phase 1 study evaluating KB304, for the treatment of wrinkles of the décolleté. Meaningful aesthetic improvements were reported following KB304 treatment with clear and statistically significant advantages over placebo as evaluated by both the investigator and subjects using the Global Aesthetic Improvement Scale (GAIS). GAIS assesses the overall aesthetic change in appearance as a result of a treatment. Subjects also reported increased satisfaction with the appearance of wrinkles, as measured by the Subject Satisfaction Questionnaire (SSQ). The SSQ is a tool to gather subject-reported outcomes providing valuable insights on the impact of treatment beyond clinical observations. Topline Efficacy Results A total of 19 subjects were enrolled, 12 were randomized to KB304 and seven to placebo. One subject dropped out before completing KB304 treatments. The remaining 18 subjects were assessed for aesthetic improvement out to three months following KB304 injections in the décolleté. The study investigator and subjects reported a clinically meaningful improvement in wrinkles one, two, and three months after treatment, as assessed by GAIS among KB304-treated subjects. Investigator Reported: At Least One-Point Improvement for Subjects Receiving: Subject Reported: At Least One-Point Improvement for Subjects Receiving: KB304 Placebo KB304 Placebo At Three Months 100% 28.6% 72.7% 14.3% At Two Months 100% 28.6% 90.9% 14.3% At One Month 100% 14.3% 72.7% 14.3% As assessed by SSQ, 81.8% of subjects receiving KB304 reported improved satisfaction with their wrinkles' appearance three months after treatment, compared to 14.3% of subjects receiving placebo. Improvements in subjects receiving KB304 were also seen across multiple additional skin attributes, as assessed by GAIS, including elasticity, crepiness, hydration, and radiance, for which the investigator reported that 100% of subjects demonstrated an improvement of at least 1 point in each of these attributes at one, two, and three months following treatment. 'We are very excited to share today's data update. We are pleased that both the investigator and subjects reported high rates of improvements across a variety of skin attributes when treated with KB304. We believe that KB304 has the potential to revolutionize the treatment of wrinkles and skin quality by directly addressing the underlying biology of aging skin. KB304 is a truly unique product candidate, which we think will address a massive gap in the market two ways…being the first product candidate to directly address elastin and by doing so in the décolleté where there are no injectable products approved. Consumers are yearning for a solution that delivers natural looking results, and KB304 has the potential to restore the skin to a more youthful appearance,' said Marc Forth, Chief Executive Officer of Jeune. The KB304 safety profile was consistent with prior clinical experience in KB301. Adverse events were mild-to-moderate and mostly reported after the first dose but substantially tapered off with subsequent doses. No severe or drug-related serious adverse events were reported. 'We are extremely excited by the promising data from the Pearl-2 study,' said Suma Krishnan, President of Research & Development at Krystal Biotech. 'We believe KB304 has the potential to be a first-in-class treatment to deliver collagen and elastin directly to the skin. This study is the first randomized, double-blind, placebo-controlled trial to investigate the potential combinatorial benefits of COL3 and elastin supplementation when produced by the body's own skin cells. On the basis of the strong results and broad improvements across multiple skin aesthetic attributes, we will be progressing KB304 into Phase 2 development for the treatment of wrinkles in the décolleté, a priority aesthetic site for which no FDA-approved injectables exist. We plan to prioritize the development of KB304 and will be meeting with the FDA in the coming months to enable initiation of the Phase 2 study.' Jeune has recently completed development and validation of a décolleté-specific photonumeric scale ('JDWS'). Jeune intends to submit the JDWS to the FDA and align on the Phase 2 study protocol in the second half of 2025 with the goal of initiating the Phase 2 study in the first half of 2026. Conference Call and Webcast Jeune and Krystal will host a conference call and webcast today, Thursday, July 24, 2025, at 4:30pm ET, to discuss the results of the PEARL-2 study, the KB304 clinical development program, Jeune's pipeline product candidates, and the strategic vision for Jeune. Investors and the general public can access the live webcast at: For those unable to listen to the live webcast, a replay will be available on the Investor's section of the Krystal website at About KB304 KB304 is an investigational aesthetic therapy employing Krystal's novel replication-defective, non-integrating HSV-1-based vector to deliver two copies of the gene encoding COL3 transgene and one copy of the gene encoding elastin to increase their levels in skin and address signs of skin aging associated with damage to the skin's extracellular matrix. KB304 is formulated as a solution for direct intradermal injection to aesthetic priority areas. About the PEARL-2 Study PEARL-2 is a Phase 1 Study of KB304, a replication-defective, non-integrating vector expressing human type III collagen (COL3) and elastin for the treatment of moderate to severe wrinkles of the décolleté. Details of the Phase 1 study can be found at under NCT identifier NCT06724900. About Jeune Aesthetics, Inc. Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal Biotech, Inc., is a biotechnology company leveraging a clinically validated gene-delivery platform to fundamentally address – and reverse – the biology of aging skin. For more information, please visit About Krystal Biotech, Inc. Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company's first commercial product, is the first-ever redosable gene therapy, and the first genetic medicine approved by the FDA and EMA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit and follow @KrystalBiotech on LinkedIn and X (formerly Twitter). Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for Krystal Biotech, Inc., or its wholly-owned subsidiary, Jeune Aesthetics, Inc., including statements about the clinical utility of KB304; KB304's ability to deliver collagen and elastin to restore the skin naturally to a more youthful appearance and potentially revolutionize the treatment of wrinkles and skin quality; KB304's potential to address a massive gap in the market; Krystal's and Jeune's plans to prioritize the development of KB304 and progress KB304 into a Phase 2 study for the treatment of wrinkles of the décolleté, including timing of meeting with the FDA and the goal of initiating the Phase 2 study in the first half of 2026; and other statements containing the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'predict,' 'project,' 'target,' 'potential,' 'likely,' 'will,' 'would,' 'could,' 'should,' 'continue,' and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: preliminary clinical data from a Phase 1 trial with a small sample size and limited follow-up may not predict results in later-stage studies; uncertainties associated with regulatory review of clinical trials, the availability or commercial potential of KB304, and such other important factors as are set forth under the caption 'Risk Factors' in Krystal's annual and quarterly reports on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Krystal's and Jeune's views as of the date of this press release. Krystal and Jeune anticipate that subsequent events and developments will cause their views to change. However, while Krystal and Jeune may elect to update these forward-looking statements at some point in the future, they specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing Krystal's and Jeune's views as of any date subsequent to the date of this press release. CONTACT Investors and Media: Stéphane Paquette, PhD Krystal Biotech spaquette@ Nishant Saxena Jeune Aesthetics nsaxena@ in to access your portfolio
